Eris Lifesciences Ltd

Eris Lifesciences Ltd

Eris Lifesciences Ltd has announced the availability of the earnings conference call recording for the quarter ended June 30, 2026, on its website.

Eris Lifesciences Ltd

Eris Lifesciences Ltd reported Q1 FY27 financial highlights, with a 14.2% YoY revenue growth and 14.5% YoY PAT growth. The company's DBF segment saw a 14% organic growth with a 35% EBIDTA margin. Eris also established an early leadership in the GLP-1 market with a 21% unit share and 20% value share. The company's insulin market share increased from 9% to 16% since the Biocon acquisition.

Eris Lifesciences Ltd

Eris Lifesciences Ltd announced its financial results for the quarter ended June 30, 2026, with the company's earnings per share (EPS) and revenue showing a significant improvement compared to the same period last year.

Eris Lifesciences Ltd

Eris Lifesciences Ltd's board meeting outcome was positive, with the company announcing the sale of its subsidiary to a related party, and the sale of its assets to a third party. The meeting also approved the company's financial results for the year ended March 31, 2022.

Eris Lifesciences Ltd

Eris Lifesciences Ltd has announced a conference call for analysts and investors to discuss its unaudited financial results for Q1 FY2027, which will be considered by the Board of Directors on July 29, 2026.

Eris Lifesciences Ltd

Eris Lifesciences Ltd has scheduled a Board of Directors meeting on July 29, 2026, to consider and approve the financial results for the quarter ended June 30, 2026.

Eris Lifesciences Ltd

Eris Lifesciences Ltd released its Corporate Presentation dated June 23, 2026, outlining its strategic direction and performance. The presentation highlights the company's position among the top-20 Indian pharma companies, with a strong focus on super-specialty segments like Anti-Diabetes and Insulins, where it holds significant market shares. It details robust R&D and manufacturing capabilities, alongside an expanding international business across 70+ countries. The company emphasizes its strategy of leveraged acquisitions, with investments exceeding INR 4,300 crore, to enter and strengthen its presence in high-value therapeutic areas such as Dermatology, Nephrology, and Injectables, signaling strong growth prospects.